| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.069 | 0.7 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |